The relationship between hirudin and activated clotting time: Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery

Anesthesia and Analgesia

Volumn 93, Issue 1, 2001, Pages 28-32

  Despotis, George J ^a   Hogue, Charles W ^a   Saleem, Rao ^a   Bigham, Matthew ^a   Skubas, Nicholas ^a   Apostolidou, Ioanna ^a   Qayum, Assad ^a   Joist, J Heinrich ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; KAOLIN; LEPIRUDIN; PROTAMINE; RECOMBINANT HIRUDIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; DOSE RESPONSE; HEART SURGERY; HEMATOCRIT; HUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0034950011     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-200107000-00007     Document Type: Article

References (27)

1. Anticoagulation monitoring during cardiac surgery: A review of current and emerging techniques
2. Heparin-induced thrombocytopenia
3. Heparin-induced thrombocytopenia in patients who undergo open heart surgery
4. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass
5. Heparinless cardiopulmonary bypass with ancrod
6. "Heparin-free" cardiopulmonary bypass: First reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass
7. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome
8. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man
9. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open-heart surgery
10. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin
11. Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass
12. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia
13. Heparin induced thrombocytopenia: Experiences in 12 heart surgery patients
14. Hirudin as anticoagulant for cardiopulmonary bypass: Importance of preoperative renal function
15. Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment - An evaluation of native blood and plasma assays
16. Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis
17. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
18. Treatment of heparin-induced thrombocytopenia
19. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: Assessment of the whole blood ecarin clotting time
20. Monitoring of recombinant hirudin: Assessment of a plasma-based ecarin clotting time assay
21. Pharmacology of r-hirudin in renal impairment
22. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT
23. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation
24. Cardiopulmonary bypass: Associated hemostatic abnormalities
25. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass
26. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations
27. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial): Evaluation of c7E3 Fab in the prevention of ischemic complications trial